Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Correlation Study Between Il-28B Gene Polymorphism (Rs8099917snp) and Sustained Virological Response in Iranian Patients With Chronic Hepatitis C Publisher Pubmed



Larijani MS1 ; Sadat SM1 ; Nikbin M2 ; Talebi SS3 ; Javadi F1 ; Mohajel N4 ; Bolhassani A1 ; Daneshvar M1 ; Aghasadeghi MR1 ; Pouriayevali MH5 ; Mapar M1
Authors

Source: Clinical Laboratory Published:2016


Abstract

Background: The current standard treatment for hepatitis C is a combination of pegylated interferon alpha and ribavirin (peg-IFNα/RBV). Recent studies have shown that single nucleotide polymorphisms (SNPs) near the in-terleukin 28B (IL28B) gene coding for IFN-X3 were associated with the antiviral treatment response. Therefore, in this study, we determined the distribution of the rs8099917 (T/G) polymorphism with sustained virological response (SVR) to chronic hepatitis C virus infection among Iranian patients. Methods: This cross-sectional study was performed on 150 blood samples based on 93 patients with chronic HCV genotypes 1 and 3 including 71 SVR positive, 22 negative, and 57 healthy individual controls. DNA was extracted from the samples and the frequency of the polymorphism was analyzed the using PCR-RFLP method. Finally, the products were detected on 3.5% agarose gel electrophoresis. Results: The analysis of the data for G/T polymorphism showed that the GG genotype was identified in 6 patients of 71 who achieved SVR, while the GT heterozygous was found in 33 patients and SVR was achieved in 19. Finally, the TT was detected in 53 patients and 7 patients were resistant to treatment. Conclusions: The results showed significant effects of G allele carriers on susceptibility to HCV infection compared to the other allele (T) in our studied population (p = 0.013, OR = 2.23, 95% CI = 1.18 - 4.21), but we did not find a significant correlation for SVR to therapy in patients with genotype TT (p = 0.055, OR = 0.48, 95% CI = 0.23-1.01). However, further studies with more samples are necessary.
Other Related Docs